Insider Selling: DexCom, Inc. (NASDAQ:DXCM) CEO Sells 32,498 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 32,498 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

DexCom Stock Performance

DXCM opened at $70.69 on Monday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market cap of $27.62 billion, a P/E ratio of 49.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The firm’s 50-day moving average price is $83.99 and its 200-day moving average price is $76.93.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on DXCM shares. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. Citigroup lifted their price objective on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Canaccord Genuity Group lifted their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

Hedge Funds Weigh In On DexCom

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its holdings in shares of DexCom by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company’s stock valued at $775,256,000 after acquiring an additional 56,094 shares in the last quarter. Jennison Associates LLC boosted its position in DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after buying an additional 710,858 shares during the last quarter. Norges Bank purchased a new stake in DexCom in the fourth quarter valued at approximately $385,367,000. Northern Trust Corp boosted its position in DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company’s stock valued at $322,454,000 after buying an additional 753,857 shares during the last quarter. Finally, Groupama Asset Managment boosted its position in DexCom by 1.1% in the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock valued at $1,912,000 after buying an additional 31,358 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.